1. Which of the following most accurately identifies the correct initial pharmacological preparation including the drug, starting dose, dose titration target, and the clinical sign confirming adequate alpha blockade?

• A) Phenoxybenzamine 5 mg orally once daily is the correct starting dose; the drug should be titrated to complete abolition of hypertensive episodes and normalization of all blood pressure readings to below 120/80 mmHg; the clinical sign confirming adequate alpha blockade is normalization of plasma metanephrine levels.
• B) Prazosin is the preferred agent for pheochromocytoma preoperative preparation because its competitive mechanism allows better titration than phenoxybenzamine; the starting dose is prazosin 1 mg at bedtime, titrated to a standing blood pressure below 100/60 mmHg; competitive alpha-1 blockade is preferred because the irreversible mechanism of phenoxybenzamine carries a risk of prolonged post-resection hypotension.
• C) Phenoxybenzamine is initiated at 10 mg orally twice daily, approximately 2-3 weeks before surgery, with dose titration upward (typically to 20-40 mg twice daily) until the patient develops postural hypotension (standing systolic typically greater than 90 mmHg), nasal congestion, and mild fatigue -- signs of adequate peripheral alpha-1 and alpha-2 blockade; the irreversible mechanism of phenoxybenzamine is specifically required because intraoperative catecholamine surges from tumor manipulation would competitively displace any reversible alpha-1 blocker at the high concentrations achieved, restoring vasoconstriction and producing dangerous hypertensive spikes despite adequate preoperative dosing; the target is not zero blood pressure episodes but adequate alpha-1 receptor occupancy confirmed by the postural hypotension and nasal congestion signs.
• D) Phentolamine 5 mg IV twice daily via central venous catheter is the correct preoperative preparation because it provides directly titratable alpha blockade and can be immediately reversed if hypotension occurs; phentolamine is preferred over phenoxybenzamine preoperatively because its competitive mechanism means post-resection hypotension will resolve faster as catecholamines clear.

2. After 2 weeks of phenoxybenzamine titrated to 30 mg twice daily, the patient develops nasal congestion, postural hypotension, and mild fatigue confirming adequate alpha blockade. The surgeon now asks about adding a beta-blocker. Which of the following most accurately identifies the correct beta-blocker addition protocol and explains why it cannot be given simultaneously with phenoxybenzamine initiation?

• A) A beta-blocker (propranolol, atenolol, or metoprolol) is now added to control the reflex tachycardia and palpitations produced by alpha-2 autoreceptor blockade (which has disinhibited NE release, increasing cardiac beta-1 stimulation) and by the baroreceptor reflex responding to vasodilation; beta blockade could not be started simultaneously with phenoxybenzamine initiation because if a beta-blocker is given before adequate alpha blockade is established, the beta-2 vasodilation that partially counterbalances the tumor's alpha-1-mediated vasoconstriction would be blocked, leaving alpha-1 vasoconstriction unopposed and potentially worsening blood pressure dangerously; only after adequate alpha blockade is confirmed is it pharmacologically safe to block beta receptors; the beta-blocker dose should be titrated to a resting heart rate of approximately 60-80 bpm.
• B) A beta-blocker is added only if the patient's heart rate exceeds 120 bpm at rest; at a resting heart rate below this threshold, beta blockade carries too high a risk of bradycardia-mediated hypotension in the context of phenoxybenzamine-induced vasodilation; the beta-blocker could not be given simultaneously with phenoxybenzamine initiation because phenoxybenzamine inhibits CYP2D6, and the drug interaction would require dose adjustment before safe administration.
• C) Beta blockade is not needed in this patient because phenoxybenzamine's alpha-2 receptor blockade actually produces a net sympatholytic effect on the heart by blocking cardiac alpha-2 receptors that normally augment NE release at cardiac synapses; the reflex tachycardia from vasodilation is self-limited and does not require pharmacological treatment.
• D) A selective alpha-1A blocker (tamsulosin) should be added rather than a beta-blocker to specifically address the cardiac symptoms; tamsulosin's alpha-1A blockade in the sinoatrial node directly slows the heart rate by a mechanism analogous to diltiazem's nodal effects.

3. The patient is now on phenoxybenzamine 30 mg twice daily and propranolol 40 mg twice daily with confirmed adequate blockade. During laparoscopic adrenalectomy, dissection of the tumor causes BP to rise to 228/144 mmHg and HR to 122 bpm. The anesthesiologist administers phentolamine 2 mg IV; BP falls to 168/102 mmHg. Two minutes later the surgeon retracts the tumor and BP spikes again to 242/152 mmHg. Which of the following most accurately identifies the best next pharmacological step?

• A) Administer IV esmolol 500 mcg/kg loading dose then 50 mcg/kg/min infusion; the heart rate of 122 bpm confirms beta-1 excess is the primary driver of the blood pressure elevation; reducing the heart rate will reduce cardiac output and lower the blood pressure; phentolamine is no longer effective because the alpha-1 receptors are saturated with agonist.
• B) Hold all antihypertensive interventions and ask the surgeon to complete the resection as rapidly as possible; once the adrenal vein is ligated the blood pressure will normalize spontaneously; any pharmacological intervention risks severe hypotension post-ligation when catecholamine support is abruptly withdrawn.
• C) Administer sodium bicarbonate 1-2 mEq/kg IV because the severe hypertension and tachycardia from massive catecholamine release has produced lactic acidosis from tissue hypoperfusion; correcting the pH with bicarbonate is the primary intervention and will restore hemodynamic stability.
• D) Administer additional IV phentolamine in 2-5 mg boluses (titrating to a target systolic BP of 120-140 mmHg) while concurrently initiating sodium nitroprusside infusion (starting at 0.25-0.5 mcg/kg/min) to maintain blood pressure control between boluses; phentolamine's competitive reversible mechanism allows rapid titration to the desired blood pressure target without overcorrecting; sodium nitroprusside provides additional vasodilation through the NO-cGMP pathway independently of adrenergic receptors, providing mechanistically complementary and more sustained blood pressure control; the anesthesiologist should alert the surgeon that continued tumor manipulation at this stage carries high cardiovascular risk and request brief pauses during pharmacological management.

4. The adrenal vein is ligated and the tumor is successfully removed. Within 90 seconds, BP falls from 178/108 to 74/42 mmHg. The anesthesiologist has administered 2 liters of crystalloid over the past 30 minutes. HR is 114 bpm. Which of the following most accurately identifies the mechanism and correct vasopressor strategy considering the ongoing phenoxybenzamine effect?

• A) The post-ligation hypotension results entirely from hypovolemia from intraoperative blood loss; phenoxybenzamine's irreversible blockade wanes completely within 6 hours of the last oral dose; standard norepinephrine infusion at 0.1-0.5 mcg/kg/min will be fully effective because alpha-1 receptors are now fully functional.
• B) The post-ligation hypotension results from two concurrent mechanisms: (1) Abrupt loss of catecholamine-driven vasoconstriction when the tumor's blood supply is severed and plasma catecholamines fall precipitously -- the vascular tone maintaining the 178/108 mmHg blood pressure is suddenly withdrawn; (2) Persistent phenoxybenzamine-mediated irreversible alpha-1 blockade that cannot be pharmacologically reversed and continues to prevent vasoconstriction for days until new alpha-1 receptor protein is synthesized; the vasopressor strategy must account for this alpha-1 blockade: aggressive continued IV fluid administration is the primary intervention; vasopressin infusion (0.03-0.04 units/min) is particularly useful because it acts through V1 receptors on vascular smooth muscle completely independent of alpha-1 receptors and unaffected by phenoxybenzamine; norepinephrine can be used but will require much higher than standard doses due to persistent alpha-1 receptor blockade -- only the fraction of newly synthesized (unblocked) alpha-1 receptors will respond; dosing must be guided by hemodynamic response rather than standard protocols.
• C) The post-ligation hypotension is caused by an anaphylactic reaction to the IV crystalloid administered intraoperatively; the combination of phenoxybenzamine and large-volume crystalloid triggers a mast cell degranulation response; the treatment is IV epinephrine followed by diphenhydramine and methylprednisolone; the standard vasopressor protocol is contraindicated.
• D) The post-ligation hypotension is caused by acute right heart failure from air embolism occurring during laparoscopic dissection; treatment is immediate repositioning of the patient (left lateral decubitus, Trendelenburg) and aspiration of air via central venous catheter.

5. At the preoperative ophthalmology visit, the patient reports his current medications to the nurse as aspirin and a blood pressure pill. He does not remember tamsulosin by name. Which of the following most accurately identifies the clinical significance of the incomplete medication history and what should be done?

• A) The omission of tamsulosin from the medication history is not clinically significant because IFIS only occurs in patients taking tamsulosin at the time of surgery; since he reports only aspirin and a blood pressure pill, the ophthalmologist can proceed with standard surgical planning.
• B) The ophthalmologist should obtain a complete medication list by contacting the patient's urologist and primary care physician before finalizing the surgical plan; IFIS risk from alpha-1 blockers persists long after drug discontinuation; the ophthalmologist cannot rely on patient recall alone for alpha-1 blocker history; if tamsulosin or any other alpha-1 blocker is identified in the medical record, full IFIS surgical preparation is required regardless of when the drug was last taken.
• C) The medication omission is clinically significant only if the patient has a known allergy to alpha-1 blockers documented in his chart; if no allergy is documented, the ophthalmologist can proceed with standard surgical protocol and manage any intraoperative complications as they arise; proactive surgical modification for potential IFIS is not evidence-based outside of confirmed tamsulosin use.
• D) The patient's statement that he takes a blood pressure pill is sufficient to trigger IFIS surgical preparation because all blood pressure medications can cause IFIS; the ophthalmologist should apply full IFIS precautions for any patient on any antihypertensive agent regardless of drug class.

6. The ophthalmologist confirms the patient has been on tamsulosin 0.4 mg daily for 5 years. The patient asks whether stopping the tamsulosin now (4 weeks before surgery) will eliminate the IFIS risk. Which of the following most accurately answers the patient's question?

• A) Yes -- stopping tamsulosin 4 weeks before surgery will fully eliminate the IFIS risk; tamsulosin's half-life is approximately 9-13 hours, meaning plasma levels are undetectable within 5 days; once plasma levels clear, iris dilator smooth muscle alpha-1A receptors fully recover normal function within 1-2 weeks; 4 weeks exceeds this recovery period by a wide margin.
• B) No -- stopping tamsulosin 4 weeks before surgery will not eliminate the IFIS risk; the ASCRS White Paper and subsequent clinical studies have established that IFIS risk persists long after tamsulosin discontinuation, and some studies report IFIS in patients who stopped tamsulosin years before cataract surgery; the mechanism of persistence is not fully elucidated but appears to involve long-lasting changes in iris dilator smooth muscle function and possibly structural iris changes that do not reverse with drug cessation; the ophthalmologist must plan full IFIS surgical preparation regardless of whether the patient continues or stops tamsulosin; stopping the drug may be recommended to reduce systemic alpha-1 blockade but should not be presented to the patient as eliminating IFIS risk.
• C) Stopping tamsulosin will partially reduce IFIS risk from 100% to approximately 40% of the risk during active therapy; a 4-week washout reduces the risk to this residual level; the ophthalmologist should use partial IFIS precautions (intracameral phenylephrine but not iris expansion devices) given the partial risk reduction.
• D) Stopping tamsulosin is strongly discouraged before cataract surgery because discontinuing the drug causes a rebound alpha-1 receptor supersensitivity in the iris dilator smooth muscle; the iris dilator becomes hypercontracted after drug withdrawal, producing paradoxical mydriasis that makes phacoemulsification more technically challenging.

7. The ophthalmologist plans to proceed with IFIS surgical modifications. A resident asks how intracameral phenylephrine addresses the pharmacological problem of IFIS. Which of the following most accurately explains the pharmacological rationale?

• A) Intracameral phenylephrine (typically 1.5% phenylephrine/1% lidocaine, diluted in balanced salt solution) is administered directly into the anterior chamber during phacoemulsification to pharmacologically stimulate the iris dilator smooth muscle; phenylephrine is a direct-acting alpha-1 agonist that activates alpha-1A receptors on iris dilator smooth muscle via Gq-IP3-Ca2+-MLCK signaling, producing active iris dilator contraction and mydriasis; in IFIS, tamsulosin's alpha-1A blockade in the iris has impaired the iris dilator's ability to actively maintain pupil dilation in response to endogenous NE; intracameral phenylephrine provides a direct alpha-1A agonist stimulus that partially overcomes the functional alpha-1A blockade by providing a very high local drug concentration directly at the iris dilator tissue, partially restoring iris dilator tone and helping maintain pupil size during the procedure; the intracameral route provides orders of magnitude higher local drug concentration than topical mydriatics, which is necessary to overcome the persistent alpha-1A functional impairment from prior tamsulosin exposure.
• B) Intracameral phenylephrine is used in IFIS because it competitively displaces tamsulosin from alpha-1A receptors in the iris dilator smooth muscle; phenylephrine has approximately 100-fold higher alpha-1A affinity than tamsulosin at the high concentrations achieved in the anterior chamber; by displacing tamsulosin from the receptor, phenylephrine restores normal alpha-1A signaling; this displacement explains why intracameral phenylephrine is effective even months or years after tamsulosin was last taken.
• C) Intracameral phenylephrine works by activating alpha-2 receptors on the ciliary muscle, producing relaxation of the ciliary body and indirect iris sphincter inhibition through a parasympathetic withdrawal mechanism; the resulting parasympathetic withdrawal allows the iris sphincter to relax, enlarging the pupil; this mechanism bypasses the tamsulosin-related iris dilator dysfunction.
• D) Intracameral phenylephrine is used purely for its vasoconstrictive properties in iris blood vessels; by constricting iris vessels, phenylephrine reduces iris blood volume, decreasing the iris's tendency to billow in response to fluid currents; the pupil-maintaining effect is secondary and results from iris shrinkage from vasoconstriction rather than any direct muscle activation.

8. After successful right-eye surgery with IFIS modifications, the patient asks the urologist whether he should switch from tamsulosin to a different BPH medication before his left-eye surgery in 3 months, particularly as he is bothered by retrograde ejaculation. Which of the following most accurately identifies the best alternative alpha-1 blocker?

• A) Switching to silodosin would be the best choice because its extreme alpha-1A selectivity produces better BPH efficacy than tamsulosin and completely eliminates IFIS risk; the retrograde ejaculation problem would also be resolved because silodosin's high selectivity for the prostate-specific alpha-1A subunit does not extend to the vas deferens alpha-1A variant.
• B) Switching to finasteride (a 5-alpha reductase inhibitor) is the best choice; without alpha-1 blockade, there is no IFIS risk for the left-eye surgery; the retrograde ejaculation problem resolves immediately upon tamsulosin discontinuation; finasteride does not cause IFIS or ejaculatory dysfunction.
• C) There is no advantage to switching alpha-1 blockers before the left-eye surgery because IFIS risk persists regardless of which alpha-1 blocker is used or whether all alpha-1 blockers are discontinued; once a patient has taken any alpha-1 blocker for more than 1 year, the iris changes are permanent and no drug switch reduces IFIS risk; the ophthalmologist must plan for IFIS regardless.
• D) Switching to alfuzosin is a reasonable option for this patient given his concern about retrograde ejaculation -- alfuzosin has the lowest incidence of ejaculatory dysfunction of all alpha-1 blockers for BPH (less than 5% retrograde ejaculation, substantially lower than tamsulosin's approximately 18%) due to its lower alpha-1A selectivity in the vas deferens and seminal vesicles; alfuzosin provides effective BPH symptom relief through tissue-selective distribution; however, IFIS risk is a class effect of all alpha-1 blockers and alfuzosin use does not eliminate IFIS risk for the left-eye surgery -- it is a lower IFIS-risk agent compared to tamsulosin but not zero risk; the ophthalmologist should still be informed of the switch and should plan modified surgical technique; the patient should also be informed that alfuzosin prolongs the QTc interval modestly, requiring ECG review and caution with QT-prolonging drug combinations.

9. The patient is worried about the heart failure risk from doxazosin. Which of the following most accurately addresses his concern using the ALLHAT data and explains the current role of doxazosin in his management?

• A) The patient's online reading is incorrect -- the ALLHAT trial found that doxazosin was associated with lower rates of heart failure compared to chlorthalidone because doxazosin's venodilation reduces cardiac preload and relieves congestion; doxazosin is actually cardioprotective and should be continued as monotherapy.
• B) The ALLHAT trial found higher heart failure rates with doxazosin compared to chlorthalidone but this finding applied only to patients over 70 years old with prior cardiac disease; in a 67-year-old without cardiac history, the ALLHAT data does not apply and doxazosin monotherapy is appropriate and safe.
• C) The patient's concern is pharmacologically valid -- the ALLHAT trial found that doxazosin was associated with significantly higher rates of combined cardiovascular disease events, particularly a nearly doubled rate of heart failure compared to chlorthalidone, despite similar blood pressure reduction, leading to early termination of the doxazosin arm; current guidelines therefore recommend against using alpha-1 blockers as first-line antihypertensive monotherapy; however, in this patient who has both hypertension and BPH responding to doxazosin for both conditions, a reasonable approach is to add a first-line antihypertensive agent (chlorthalidone, amlodipine, or ACE inhibitor) rather than discontinue doxazosin, continuing the doxazosin as add-on therapy for both conditions while a first-line agent carries the primary antihypertensive burden; the heart failure risk in ALLHAT was seen in comparison to chlorthalidone and does not mean doxazosin causes heart failure in absolute terms, but the relative risk supports not relying on it as the sole antihypertensive.
• D) The ALLHAT heart failure finding with doxazosin has been retracted in a subsequent re-analysis that corrected for baseline differences between treatment groups; the retraction established that doxazosin and chlorthalidone have equivalent cardiovascular outcomes when properly adjusted; doxazosin monotherapy is therefore fully endorsed as a first-line antihypertensive in current post-ALLHAT guidelines.

10. The internist adds chlorthalidone 12.5 mg daily to the regimen and the patient's BP reaches 126/78 mmHg at 6 weeks. The patient now asks about sildenafil for ED. Which of the following most accurately identifies the hemodynamic interaction between doxazosin and sildenafil and how it should be explained to the patient?

• A) Sildenafil is absolutely contraindicated with doxazosin under all circumstances; the FDA black-box warning prohibits this combination at any dose of either drug; the patient must choose between doxazosin for BPH or sildenafil for ED, as co-administration poses an unacceptable risk of fatal hypotension that cannot be mitigated by dose adjustment or timing.
• B) Sildenafil is safe to use with doxazosin without any special precautions because doxazosin's long half-life means it is always at steady-state with no meaningful fluctuation in plasma levels; since there is no peak plasma concentration fluctuation, there is no high-risk period for drug interaction with sildenafil; the interaction only occurs when doxazosin levels are rising, which does not happen at steady-state.
• C) The hemodynamic interaction between doxazosin and sildenafil is exclusively pharmacokinetic -- doxazosin inhibits CYP3A4, the primary enzyme metabolizing sildenafil; the resulting 4-fold increase in sildenafil AUC from pharmacokinetic inhibition produces excessive PDE5 inhibition and hypotension; the interaction is managed by reducing sildenafil to 12.5 mg.
• D) The hemodynamic interaction between doxazosin and sildenafil is minimal because they act on different vascular beds; doxazosin primarily affects the renal vasculature while sildenafil primarily affects the penile vasculature; since these are different vascular territories, the vasodilatory effects do not summate clinically; the patient can take sildenafil 50 mg without dose modification.
• E) The hemodynamic interaction between doxazosin and sildenafil is a real, class-effect pharmacodynamic interaction: doxazosin blocks alpha-1B receptors on systemic vascular smooth muscle, reducing norepinephrine-mediated vasoconstriction and lowering systemic vascular resistance; sildenafil inhibits PDE5 in vascular smooth muscle, increasing cGMP and producing vasodilation via the NO-cGMP-PKG-MLCK dephosphorylation pathway independently of adrenergic receptor activity; these two independent vasodilatory mechanisms are additive and can produce clinically significant hypotension, particularly orthostatic hypotension within 2-6 hours of sildenafil ingestion; doxazosin, as a non-uroselective alpha-1 blocker with significant alpha-1B vascular activity, has a more pronounced hemodynamic interaction with sildenafil than uroselective agents; management: start sildenafil at the lowest available dose (25 mg rather than 50 mg); counsel the patient to avoid sudden postural changes within several hours of taking sildenafil; advise taking sildenafil at a time when doxazosin concentrations are closer to trough; ensure adequate hydration; the combination is not absolutely contraindicated but requires patient counseling and dose precautions.

11. The internist decides to prescribe sildenafil but wants to minimize the hemodynamic risk. She considers whether the patient could be switched from doxazosin to a uroselective alpha-1 blocker to reduce the interaction severity while maintaining BPH control. Which of the following most accurately identifies the safest alpha-1 blocker choice in a patient who also needs a PDE5 inhibitor?

• A) Tamsulosin is the safest alpha-1 blocker choice in combination with a PDE5 inhibitor because its uroSelectivity means it has zero effect on systemic vascular alpha-1 receptors and therefore zero hemodynamic interaction with sildenafil; once switched to tamsulosin, sildenafil can be prescribed at the standard 50 mg dose without any dose modification or hemodynamic precautions.
• B) Tamsulosin (or silodosin) represents a pharmacologically safer alpha-1 blocker choice than doxazosin in a patient who also needs a PDE5 inhibitor; the uroSelectivity of tamsulosin (preferentially blocking alpha-1A and alpha-1D in the lower urinary tract over alpha-1B in systemic vasculature) means that substantially less alpha-1B vascular tone is reduced compared to doxazosin; the additive vasodilation with sildenafil is therefore less pronounced; however, the interaction is not eliminated -- even uroselective alpha-1 blockers produce some systemic vasodilation and the PDE5 inhibitor interaction is still present at a lower magnitude; sildenafil should still be started at 25 mg in patients on any alpha-1 blocker; the switch to tamsulosin would also address this patient's BPH symptoms (the primary indication) while the hypertension benefit of doxazosin would be covered by the chlorthalidone already added to the regimen.
• C) Phenoxybenzamine is the safest alpha-1 blocker in combination with a PDE5 inhibitor because its irreversible receptor blockade eliminates all variability in hemodynamic interaction -- since all alpha-1 receptors are completely blocked, adding sildenafil produces no additional vasodilation beyond what phenoxybenzamine already provides; the hemodynamic state is stable and predictable.
• D) Alfuzosin is preferred over tamsulosin for this patient specifically because of ED -- alfuzosin's alpha-1A blockade in the corpus cavernosum is stronger than tamsulosin's, producing direct pharmacological facilitation of penile erection; alfuzosin therefore provides both BPH benefit AND contributes to ED treatment, potentially allowing a lower sildenafil dose; the reduced sildenafil dose further minimizes the hemodynamic interaction.

12. The patient is switched to tamsulosin 0.4 mg daily (taken with breakfast) and chlorthalidone 12.5 mg daily. Sildenafil 25 mg is prescribed as needed. He asks when he should take the sildenafil in relation to his tamsulosin to minimize dizziness risk. Which of the following most accurately provides the optimal timing guidance?

• A) The patient should take sildenafil in the evening, approximately 4-6 hours after his morning tamsulosin dose; this timing places sildenafil's peak vasodilatory effect (occurring approximately 60-90 minutes after oral ingestion) at a time when tamsulosin is past its own Cmax and declining toward trough; tamsulosin's half-life is approximately 9-13 hours, so 4-6 hours after the morning dose still represents substantial tamsulosin plasma levels (approximately 65-75% of Cmax), meaning the overlap is reduced but not eliminated; the patient should be counseled that even with this timing strategy some hemodynamic interaction persists and he should avoid rising suddenly from a lying position within 4 hours of taking sildenafil; he should take sildenafil on an occasion when he is not dehydrated, has eaten adequately, and can remain in a position to sit or lie down if he feels lightheaded; if the 25 mg dose is well-tolerated hemodynamically over several uses, the dose may be increased to 50 mg with continued hemodynamic monitoring.
• B) The patient should take sildenafil at the same time as his morning tamsulosin to ensure that both drugs are always at similar pharmacokinetic phases relative to each other; taking them at different times creates unpredictable pharmacokinetic windows that make the hemodynamic interaction less predictable; co-administration at the same time allows the interaction to be consistent and manageable.
• C) The patient should take tamsulosin in the evening rather than the morning and take sildenafil in the morning; the 12-hour separation ensures tamsulosin is at its 12-hour trough level when sildenafil is ingested; at this trough level, tamsulosin's alpha-1B vascular activity is negligible and the hemodynamic interaction with sildenafil is clinically insignificant; this timing strategy completely eliminates the hypotension risk.
• D) Timing of sildenafil relative to tamsulosin does not matter because tamsulosin reaches steady state within 5-7 days of once-daily dosing; at steady state, tamsulosin plasma concentrations fluctuate only minimally (peak-to-trough ratio approximately 1.3:1); this minimal fluctuation means the pharmacodynamic interaction with sildenafil is constant throughout the day regardless of timing; the patient should take sildenafil whenever convenient.

13. Which of the following most accurately identifies the pharmacological mechanism by which prazosin addresses PTSD nightmares and explains why the therapeutic dose for this indication is typically much higher than standard antihypertensive doses?

• A) Prazosin addresses PTSD nightmares through peripheral blood pressure reduction -- by lowering nighttime blood pressure, prazosin reduces the cardiovascular physiological arousal that wakes patients from nightmares; the dose-response relationship for nightmare suppression tracks directly with the degree of blood pressure lowering; the mechanism is entirely peripheral and does not involve any central noradrenergic circuitry.
• B) Prazosin addresses PTSD nightmares by globally suppressing REM sleep at higher doses; at doses of 5-15 mg, prazosin reaches sufficiently high plasma concentrations to cross the blood-brain barrier and suppress REM sleep-generating circuits in the brainstem; since PTSD nightmares occur during REM sleep, suppressing REM eliminates nightmare occurrence.
• C) Prazosin addresses PTSD nightmares through central serotonin receptor agonism -- at high plasma concentrations, prazosin activates 5-HT2A receptors in the amygdala producing an anxiolytic and fear memory consolidation-blocking effect; this serotonergic mechanism is independent of alpha-1 receptor blockade.
• D) Prazosin addresses PTSD nightmares through central alpha-1 adrenergic receptor blockade in the noradrenergic projection circuits from the locus coeruleus to the amygdala, prefrontal cortex, and hippocampus; in PTSD, chronic locus coeruleus hyperactivation produces elevated norepinephrine in these circuits, driving amygdala hyperactivation, fear memory reconsolidation, and the intrusive nightmare activity that characterizes REM sleep in PTSD; prazosin crosses the blood-brain barrier (it is lipophilic) and blocks central alpha-1 receptors, reducing NE-mediated amygdala activation and attenuating the hyperarousal-driven nightmare generation; the dose needed for meaningful central alpha-1 receptor occupancy in these circuits is substantially higher than the dose needed for peripheral alpha-1B vascular blockade, because brain penetration is limited by the blood-brain barrier and the central therapeutic target requires adequate CNS concentrations that necessitate higher plasma levels; this is why patients may require 5-15 mg at bedtime for nightmare suppression while maintaining acceptable blood pressure.

14. The psychiatrist initiates prazosin 1 mg at bedtime. The patient asks why he cannot start at a higher dose immediately if a higher dose is ultimately needed for nightmares. Which of the following most accurately explains why slow titration is pharmacologically necessary?

• A) Slow titration of prazosin is necessary because the drug requires 4-6 weeks to achieve pharmacological steady-state in the central noradrenergic circuits; starting at a higher dose does not accelerate the timeline for nightmare suppression because the central receptor adaptations require weeks of drug exposure to develop; the slow titration is about waiting for the pharmacodynamic mechanism to engage rather than preventing any adverse effect.
• B) Slow titration of prazosin is necessary to prevent tachyphylaxis -- if prazosin is started at a high dose, alpha-1 receptors on peripheral vascular smooth muscle undergo rapid GRK-mediated phosphorylation and internalization in response to prolonged blockade, producing receptor downregulation that eliminates both the antihypertensive and the nightmare-suppressing effects within 2-3 weeks; starting at 1 mg prevents this tachyphylaxis by exposing receptors to sub-saturating drug concentrations.
• C) Slow titration of prazosin is necessary to prevent the first-dose phenomenon -- acute orthostatic hypotension that can produce dizziness, lightheadedness, and syncope; prazosin blocks alpha-1 receptors on both arteriolar resistance vessels (reducing SVR) and venous capacitance vessels (increasing venous pooling and reducing venous return); on the first dose, neither the baroreflex nor the renin-angiotensin-aldosterone system has had time to adapt to the vasodilation, making the blood pressure fall more dramatic than at subsequent doses; starting at 1 mg at bedtime (with the patient recumbent) limits the magnitude of the initial vasodilation to a period when gravitational orthostasis is minimized; subsequent dose increments (typically 1-2 mg every 1-2 weeks based on tolerance) allow cardiovascular adaptations to develop between increments, reducing the risk of symptomatic orthostatic hypotension at each new dose level; this is particularly important in this patient whose baseline blood pressure of 134/82 mmHg is at the lower end of what can tolerate significant pharmacological reduction without symptomatic hypotension.
• D) Slow titration of prazosin is necessary because the drug undergoes autoinduction of its own metabolism -- prazosin induces CYP3A4 expression with repeated dosing, progressively increasing its own clearance; starting at 1 mg is necessary because the apparent half-life shortens as doses increase, and starting at a higher dose before autoinduction has occurred would produce much higher plasma concentrations than intended.

15. The patient asks whether yohimbine (an herbal supplement marketed for weight loss and sexual enhancement) might also help his PTSD symptoms through a similar mechanism to prazosin. Which of the following most accurately explains why yohimbine would worsen rather than help PTSD symptoms?

• A) Yohimbine would worsen PTSD because it inhibits monoamine oxidase-A in the central nervous system, increasing synaptic NE, dopamine, and serotonin levels simultaneously; the excess serotonin would cause serotonin syndrome and the excess NE would worsen the PTSD hyperarousal state.
• B) Yohimbine would worsen PTSD because it activates alpha-1 receptors in the amygdala as a direct agonist -- the same receptors prazosin blocks; yohimbine's alpha-1 agonist activity in the amygdala potentiates fear memory consolidation and increases NE-mediated amygdala hyperactivation; this is why yohimbine and prazosin are pharmacological opposites -- yohimbine is the agonist and prazosin the antagonist at the same receptor.
• C) Yohimbine would worsen PTSD because it blocks serotonin reuptake through SERT inhibition as a secondary mechanism in addition to its alpha-2 antagonism; the SERT inhibition raises synaptic serotonin, which activates 5-HT2A receptors in the amygdala to increase fear memory consolidation.
• D) Yohimbine would have no effect on PTSD symptoms because its alpha-2 receptor antagonism operates exclusively in the peripheral sympathetic nervous system; it does not cross the blood-brain barrier and has no central nervous system pharmacological activity; PTSD symptoms are centrally driven and are therefore unaffected by peripheral alpha-2 antagonism.
• E) Yohimbine would worsen PTSD symptoms through the exact pharmacological opposite of prazosin's therapeutic mechanism: prazosin blocks central alpha-1 receptors (reducing NE-mediated amygdala hyperactivation, attenuating the fear circuit hyperarousal driving nightmares); yohimbine blocks central presynaptic alpha-2 autoreceptors on LC neurons projecting to the amygdala and prefrontal cortex, removing the negative feedback on NE release from these neurons and INCREASING central NE release in the exact circuits that prazosin is trying to dampen; additionally, yohimbine blocks postsynaptic alpha-2 receptors in the brainstem, increasing central sympathetic outflow; the net effect of yohimbine is a surge in central and peripheral NE -- precisely what PTSD patients have in excess; yohimbine has been used experimentally as a pharmacological model to INDUCE PTSD-like hyperarousal states and panic attacks; clinical research has demonstrated that yohimbine provocation produces more pronounced anxiety, increased heart rate, and physiological hyperarousal in PTSD patients compared to controls; this patient should be strongly advised against yohimbine use, which could precipitate a PTSD hyperarousal episode, worsen nightmares, and trigger panic attacks.

16. After 8 weeks of prazosin titrated to 6 mg at bedtime, the patient reports dramatic reduction in nightmare frequency (from nightly to 1-2 times per week), improved sleep quality, and reduced daytime hyperarousal. His blood pressure is now 118/72 mmHg. The psychiatrist wants to continue prazosin long-term. Which of the following most accurately identifies the monitoring requirements and considerations for long-term prazosin use in this patient?

• A) Long-term prazosin use requires monthly cardiac catheterization because sustained alpha-1 blockade at doses of 6 mg produces progressive coronary vasoconstriction as a compensatory response to the peripheral vasodilation; the coronary constriction is mediated by endothelin-1 release triggered by the baroreceptor reflex; monthly catheterization detects progressive coronary narrowing before clinical ischemia develops.
• B) Long-term prazosin use for PTSD in this patient requires monitoring of: (1) Blood pressure at each visit -- supine and standing measurements; his BP has fallen to 118/72 mmHg (lower than baseline of 134/82 mmHg) on 6 mg prazosin; the reduction is in a beneficial direction for this borderline-hypertensive patient, but at higher prazosin doses symptomatic orthostatic hypotension can develop and requires dose reduction; (2) Nightmare frequency and PTSD symptom scores (PCL-5 [PTSD Checklist for DSM-5] or similar) to assess ongoing therapeutic response and determine whether dose adjustment is needed; (3) Drug interactions -- if new medications are added that are alpha-1 blockers, vasodilators, or PDE5 inhibitors, the hemodynamic interaction risk increases and blood pressure monitoring should be intensified; (4) Awareness of the alpha-1 blocker class effect on cataract surgery (IFIS) -- if this patient ever requires cataract surgery, the ophthalmologist must be informed of prazosin use regardless of when it was discontinued; (5) Periodic reassessment of PTSD symptoms to determine whether psychotherapy advancement, prazosin dose reduction, or continuation is appropriate; there is no established maximum duration of prazosin therapy for PTSD -- it can be used long-term if symptoms require it and it is well-tolerated; abrupt discontinuation should be avoided as it may produce return of nightmares; tapering is preferred if discontinuation is planned.
• C) Long-term prazosin use at 6 mg nightly produces cumulative irreversible alpha-1 receptor downregulation in peripheral vascular smooth muscle after 6-12 months; this receptor loss creates drug dependence because blood pressure regulation becomes entirely dependent on the continued alpha-1 blockade; abrupt discontinuation after 6 months of high-dose prazosin produces a dangerous withdrawal syndrome (rebound hypertension analogous to clonidine withdrawal) requiring hospitalization; the patient must be informed that once 6 mg prazosin is started, it cannot be stopped without a very slow taper over 6-12 months.
• D) The most important long-term monitoring requirement for prazosin in PTSD is monthly plasma prazosin level measurements; prazosin has significant pharmacokinetic variability between patients; some patients develop accelerated hepatic metabolism over time leading to subtherapeutic plasma levels and nightmare relapse; monthly prazosin plasma levels allow dose titration to maintain concentrations in the therapeutic range of 0.5-2.0 ng/mL established by pharmacokinetic-pharmacodynamic modeling of the Raskind clinical trials.